About Broad Street Alerts: — ContraVir Pharma (CTRV)
Big opportunities in Small Cap’s
Broadstreetalerts.com recent profiles and track record, 157% in verifiable potential gains for our
members in December 2015 alone.
December 29th, 2015- (NASDAQ: INVT) opened $1.35/share hit a high midday of $2.82/share over 100%
in gains for our members
December 15th, 2015-(NYSE-MKT: XXII) opened at $1.29 hit a high of $1.54 within 3 days for gains of
19% for our members.
December 2nd, 2015- (NASDAQ: TCCO) opened at $3.25 hit a high of $4.50 within 3 days for 38% gains
for our members.
***IN PLAY- Current profile sent at 3pm on March 24th, 2016 to our members up 17% so far (NASDAQ:
ICLD) full profile- https://broadstreetalerts.com/wp-content/uploads/2016/03/ICLD-profile.pdf
These are numbers that make traders drool. Any trader in any market would fall all over themselves to
see numbers like this. So if you’ve been on the fence, perhaps it’s time to start doing some research and
verify our numbers for yourself. We are constantly raising the bar and separate ourselves from the rest
of the small-cap newsletters as the best in business. We know with a large following comes a large
responsibility as we have everyone from institutional investors to the beginner following our profiled
securities in our newsletters. This is something we take very seriously always seeking small cap growth
companies that have both near and long-term potential for our members.
***Get our small cap profiles, special situation and watch alerts in real time. We are now offering our
VIP SMS/text alert service for free, simply text the word “Alerts” to the phone number 25827 from your
cell phone.
ContraVir Pharma (CTRV)
ContraVir Pharmaceuticals, a biopharmaceutical with a market cap of just over $50 million, gained 30% Tuesday morning after it said its CMX157 outperforms Gilead’s (Nasdaq: GILD) Tenofovir AF (TAF) in Hepatitis B virus.
The company’s press release said:
ContraVir Pharmaceuticals, Inc. (NASDAQ: CTRV), a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, reported positive results from a third-party in vitro study that further validates CMX157’s profile as a highly potent anti-hepatitis B drug. In this first head-to-head in vitro study, CMX157 compared favorably to tenofovir alafenamide fumarate (TAF), which was approved recently by the US Food and Drug Administration (FDA) as part of a four-drug combination therapy for HIV-1 (Genvoya®), and is currently under development by Gilead Sciences Inc. (GILD) for treating chronic hepatitis B infection. ContraVir recently initiated a Phase 1/2a clinical study of CMX157, which is currently enrolling healthy volunteers and is anticipated to begin enrolling hepatitis B patients in the second quarter 2016.
The study compared the anti-hepatitis B activities of CMX157 and other tenofovir prodrugs, including tenofovir DF (Viread®), in order to profile CMX157 among this important class of antiviral therapies. The study findings revealed that CMX157 and TAF were similarly potent against hepatitis B virus (HBV), with CMX157 trending toward higher potency (EC50 = 9.3 ± 3.6 nM vs. 32.4 ± 17.1 nM for CMX157 and TAF, respectively; and EC90 = 186 ± 53 nM vs 474 ± 261 nM for CMX157 and TAF, respectively). Furthermore, viral rebound studies showed that CMX157 demonstrates best-in-class duration of activity. Nine days following incubation with HBV, using two different experimental conditions, one at equimolar and one at EC90 concentrations, CMX157 showed two- to three-fold reduced viral rebound compared to TAF. The study also confirmed earlier results, as reported previously by ContraVir, regarding the significantly increased potency of CMX157 compared to tenofovir.
Source : Street Insider
SCS LLC has not been compensated for this article.
SCS LLC was previously compensated up to twenty thousand dollars each by star media llc for the mention of INVT and XXII however those contracts have expired.
